Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

Inclusion Criteria: * Must have histologically confirmed neuroblastoma or osteosarcoma that is recurrent or refractory and for which standard curative measures do not exist or are no longer effective. Must have histologic verification of their disease at diagnosis or at relapse * Patients with osteosarcoma in the dose escalation cohort, must have evaluable or measurable disease at enrollment * Patients with osteosarcoma in the expansion cohort must have measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) at enrollment * Patients with neuroblastoma in the dose escalation or dose the expansion cohort must have: * Prior progressive disease OR refractory disease present since diagnosis AND at least one of the following: * Evidence of tumor in the bone marrow (BM) * At least one metaiodobenzylguanidine (MIBG)-avid soft tissue or skeletal site * For MIBG-nonavid disease, at least one FDG-PET- positive soft tissue or skeletal site plus past histologic confirmation * Progressive disease is defined as any disease progression occurring at any time after the diagnosis of high-risk neuroblastoma. Refractory disease is defined as an incomplete response of high-risk neuroblastoma to all treatments but without disease progression * Must be \< 40 years of age * There is no limit to the number of prior treatment regimens. The following washout periods prior to leukapheresis apply to patients undergoing leukapheresis on this study. If…